---
title: Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer
nct_id: NCT06904625
overall_status: RECRUITING
phase: NA
sponsor: Institut Claudius Regaud
study_type: INTERVENTIONAL
primary_condition: Metastatic Breast Cancer
countries: France
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT06904625.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06904625"
ct_last_update_post_date: 2025-08-19
last_seen_at: "2026-05-12T06:01:41.490Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Comparison of Different Methods of CAPTure of Circulating Tumour Cells (CTC) in Patients With Metastatic Breast or Prostate Cancer

**NCT ID:** [NCT06904625](https://clinicaltrials.gov/study/NCT06904625)

## Key Facts

- **Status:** RECRUITING
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 36
- **Lead Sponsor:** Institut Claudius Regaud
- **Conditions:** Metastatic Breast Cancer, Metastatic Prostate Cancer
- **Start Date:** 2025-08-14
- **Completion Date:** 2026-05
- **CT.gov Last Update:** 2025-08-19

## Brief Summary

This trial is a pilot, prospective, single-center study conducted in a population of patients with metastatic breast cancer (whatever the immunohistochemical subtype) or metastatic prostate cancer. The aim of this exploratory study is to compare the sensitivity of three different techniques (CellSearch®, Parsortix® and SmartCatch®) in detecting circulating tumor cells (CTCs). After the patient's agreement, and before starting anti-tumor treatment, a blood sample will be taken using the 3 different CTC detection techniques.

Each patient will participate in the study for one day.

A total of 36 evaluable patients (18 patients with metastatic breast cancer and 18 patients with metastatic prostate cancer) will be included in this interventional study.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Patient with breast cancer (whatever the immunohistochemical subtype: triple-negative, RH+/HER2-negative or HER2-positive) or prostate cancer, multi-metastatic, eligible for a new line of treatment.
2. Patient not yet initiated on a new specific treatment for breast or prostate cancer at inclusion.
3. Age ≥ 18 years and WHO ≤ 2
4. Patient affiliated to Social Security scheme in France.
5. Patient having signed informed consent prior to inclusion in the study and prior to any study-specific procedures.

Exclusion Criteria:

1. Associated pathology(ies) likely to prevent the study procedure from running smoothly
2. Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures stipulated in the study protocol.
3. Patient deprived of liberty or under legal protection (guardianship, legal protection)
4. Patient who has had another solid tumor (excluding carcinoma in situ of the breast or cervix) within 5 years.
```

## Arms

- **Patients with metastatic breast cancer or prostate cancer** (OTHER)

## Interventions

- **Taking blood samples before starting treatment** (OTHER) — For each patient included, a blood sample will be taken (37 mL in total) for the CTCs detection using the 3 techniques (CellSearch®, Parsortix® and SmartCatch®).

For 3 patients only, an additional blood volume (18 mL) will also be collected for tcDNA detection (exploratory analysis of 3 patients).

## Primary Outcomes

- **The rate of patients with at least one additional CTC detected by the SmartCatch® method compared with the standard approach (CellSearch®).** _(time frame: 9 months after the study start)_ — It is defined by the ratio of the number of patients with at least one additional CTC detected by the SmartCatch® method compared with the standard approach (CellSearch®) to the total number of patients.

## Secondary Outcomes

- **The rate of patients with CTCs (CK+/CD45-) detected by each technique (CellSearch®, Parsortix® and SmartCatch®).** _(time frame: 9 months after the study start)_
- **The number of total CTCs (EpCAM+/CK+/CD45- and EpCAM-/CK+/CD45-) detected by the different techniques (CellSearch®, Parsortix® and SmartCatch®).** _(time frame: 9 months after the study start)_

## Locations (1)

- IUCT-O, Toulouse, France — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.iuct-o|toulouse||france` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT06904625.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT06904625*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*